论文部分内容阅读
为探讨含有缬氨酸、亮氨酸、异亮氨酸的肝氨散(口服BCAA)治疗,预防肝昏迷的机理,本文对口服BCAA制剂进行了一系列血浆氨基酸平衡作用的实验室研究。17例肝硬化病人,随机为分两组,一组10例口服BCAA制剂后,血浆中BCAA明显升高,支链氨基酸与芳香族氨基酸的克分子比值(BCAA/AAA比值)明显升高,而与肝昏迷发病有关的蛋氨酸、酪氨酸、苯丙氨酸、游离色氨酸、血氨等显著减低。并与另一组7例使用静脉BCAA后,进行了药物动力学的比较。
To investigate the mechanism of hepatic ammonia powder (BCAA) containing valine, leucine, and isoleucine to prevent hepatic coma, a series of laboratory studies on the balance of plasma amino acids in oral BCAA preparations were conducted in this paper. Seventeen patients with cirrhosis were randomized into two groups. One group of 10 oral BCAA preparations showed a marked increase in BCAA, and the ratio of branched-chain amino acids to aromatic amino acids (BCAA / AAA ratio) was significantly increased. However, The incidence of hepatic coma methionine, tyrosine, phenylalanine, free tryptophan, ammonia and other significantly reduced. Pharmacokinetic comparisons were performed with another group of 7 patients after intravenous administration of BCAA.